ReviewHepatology (Baltimore, Md.)2019
Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
Review in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04162938 (Use of a Patient-Centered Electronic App to Increase Emergency Department Patient's Knowledge on HCV Infection, Disease Progression, and Care to Improve the HCV Care Continuum), which is not on this map. Cited by 290 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of a Patient-Centered Electronic App to Increase Emergency Department Patient's Knowledge on HCV Infection, Disease Progression, and Care to Improve the HCV Care Continuum
Who cites it
290 citing papers in PubMed, 4 syntheses or guidelines pooled it, 484 citations in OpenAlex.
- Racial and ethnic disparities in alcohol-associated liver disease in the United States: A systematic review and meta-analysis.Hepatology communications · 2024Pooled it
- Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2022Pooled it
- Prevalence and Management of Sexually Transmitted Infections in Correctional Settings: A Systematic Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation.The Journal of infectious diseases · 2025Trial
- Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.PloS one · 2024Trial
- Shame and stigma in association with the HCV cascade to cure among people who inject drugs.Drug and alcohol dependence · 2023Trial
- Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study.Journal of general internal medicine · 2022Trial
- A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.Hepatology (Baltimore, Md.) · 2021Trial
- Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020.American journal of preventive medicine · 2026Article
- Is Geenius HCV Supplemental Assay an Alternative to HCV Confirmatory Western Blot INNO-LIA HCV Score in Repeatedly Reactive Blood Donations After First Line Screening?Journal of clinical laboratory analysis · 2026Article
- Racial and Ethnic differences in Chronic Hepatitis C Infection Prevalence and Mortality Among Inpatients with Coronary Artery Disease in the United States, 2016 to 2021.Journal of racial and ethnic health disparities · 2026Observational
- Increases in Hepatitis C Virus (HCV) Treatment and Cure Among People Who Inject Drugs in the Seattle Area Between 2018 and 2022.AIDS and behavior · 2026Review
- Article
- Risk assessment and mitigation of hepatitis C virus RNA carryover contamination in a reflex testing algorithm.Journal of clinical microbiology · 2026Article
- Patients Experiencing Homelessness Have Higher Complication Rates After Total Shoulder Arthroplasty.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
- Projected health benefits and cost offsets from the United States National Hepatitis C Elimination Initiative.Nature communications · 2026Article
- Development and validation of a machine learning model for evidence of prior or current HCV infection: a demographic screening approach for the US population.BMC public health · 2026Article
- Street-Based Hepatitis C Treatment and Patient Experiences Among Adults Experiencing Unsheltered Homelessness.JAMA network open · 2026Article
- Identifying communities at elevated risk of hepatitis C infection in Los Angeles County: an ecological study using machine learning.BMC public health · 2026Article
230 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byReply.2019
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. To update the estimated HCV prevalence among all adults aged ≥18 years in the United States, we analyzed 2013-2016 data from the National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of HCV in the noninstitutionalized civilian population and used a combination of literature reviews and population size estimation approaches to estimate the HCV prevalence and population sizes for four additional populations: incarcerated people, unsheltered homeless people, active-duty military personnel, and nursing home residents. We estimated that during 2013-2016 1.7% (95% confidence interval [CI], 1.4-2.0%) of all adults in the United States, approximately 4.1 (3.4-4.9) million persons, were HCV antibody-positive (indicating past or current infection) and that 1.0% (95% CI, 0.8-1.1%) of all adults, approximately 2.4 (2.0-2.8) million persons, were HCV RNA-positive (indicating current infection). This includes 3.7 million noninstitutionalized civilian adults in the United States with HCV antibodies and 2.1 million with HCV RNA and an estimated 0.38 million HCV antibody-positive persons and 0.25 million HCV RNA-positive persons not part of the 2013-2016 NHANES sampling frame. Conclusion: Over 2 million people in the United States had current HCV infection during 2013-2016; compared to past estimates based on similar methodology, HCV antibody prevalence may have increased, while RNA prevalence may have decreased, likely reflecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality among the HCV-infected population; efforts on multiple fronts are needed to combat the evolving HCV epidemic, including increasing capacity for and access to HCV testing, linkage to care, and cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.